Audio Journal of Prostate Cancer Special Edition 2005
Reporting from:
2005 Multidisciplinary Prostate Cancer Symposium, February 17-19, Hyatt Grand Cypress, Orlando, Florida
Scientific Editors:
George Canellos, Dana-Farber Cancer Institute, Boston
Gordon McVie, European Institute of Oncology, Milan
Pat Price, Christie Hospital, Manchester
Gianni Bonadonna, Istituto Nazionale Tumori, Milan
Producer: Derek Thorne
In this edition:
Will they or won’t they relapse? For patients with prostate cancer, their PSA velocity before radical prostatectomy best pinpoints the risk of relapse, according to Deep Patel.
Brachytherapy, rather than external beam radiation, may be the best option for patients with intermediate-risk prostate cancer, according to Vinai Gondi.
David Dearnaley has been using the latest precision radiotherapy tool, Intensity Modulated Radiotherapy – IMRT, successfully to treat affected nodes in locally advanced prostate cancer.
A new study reveals the possibility of extending life among patients with androgen independent prostate cancer. Eric Small discusses the final survival data from a phase-three trial of the vaccine APC 8015.
Abstract 68
Deep Patel, Stanford University School of Medicine
In an investigation of 200 patients with prostate cancer the rate of change of prostate specific antigen levels before radical prostatectomy proved to be an independent prognostic factor for the risk of relapse.
Abstract 74
Vinai Gondi, Columbia University, New York
An investigation of brachytherapy found that it gave superior biochemical disease-free survival among 350 patients diagnosed as having intermediate-risk prostate cancer.
Abstract 58
Carl Rossi, Loma Linda University Medical Center
The use of a proton-beam boost -as part of a high-dose conformal radiotherapy schedule – has brought big advantages among patients with low or intermediate risk prostate cancer.
COMMENT: Mack Roach, UCSF Comprehensive Cancer Center, San Francisco
Abstract 59
Joycelyn Speight, UCSF Comprehensive Cancer Center
A study of 2 000 patients found no difference in sexual dysfunction between the treatment options available for prostate cancer patients by the time follow up goes out to four years. But brachytherapy still had the least impact on quality of life early on in treatment.
COMMENT: Mack Roach, UCSF Comprehensive Cancer Center, San Francisco
Abstract 179
David Dearnaley, Royal Marsden Hospital, Institute of Cancer Research, Surrey
Intensity Modulated Radiotherapy – IMRT has been used successfully to treat affected nodes in locally advanced disease.
Abstract 264
Eric Small, University of California, San Francisco
The possibility of extending life among patients with androgen independent prostate cancer has emerged from a new study. The final survival data presented from a phase-three randomized placebo-controlled trial of the vaccine APC 8015 show a positive benefit.
Abstract 268
Matthew Smith, Massachusetts General Hospital, Boston
Among patients with non-metastatic disease, rising PSA despite androgen deprivation therapy is still consistent with an indolent natural history. Baseline PSA, however, along with PSA velocity, independently predicts bone metastasis and survival.
Abstract 282
Pierre Major, McMaster University, Ontario
Palliative use of bisphosphonates off-study has now been investigated by a multiple event analysis which allows for changing event rates and varying patient survival. Using zoledronic acid can significantly reduce the need for bone irradiation in patients with advanced disease.
Abstract 62
Mack Roach, UCSF Comprehensive Cancer Center, San Francisco
Predicting aggressive disease may be easier following results from a study looking at the tumor suppressor gene p53. Mingxin Che from Wayne State University in Detroit presented data on disease progression and survival among nearly 800 patients with locally advanced prostate cancer. Mack Roach discusses the significance of Dr Che’s results.
